Wednesday, June 13, 2018

(LML) Single-dose rifampicin chemoprophylaxis

Leprosy Mailing List – June 13,  2018

Ref.:  (LML) Single-dose rifampicin chemoprophylaxis 

From:  Carlos Gustavo Wambier, Ponto Grosso, Brazil


 

Dear Colleagues,

 

I completely agree with Jaison (LML, June 12, 2018).  The pivotal point is to teach leprosy to all physicians in all countries. It is NOT uncommon to see a diabetic patient labeled with diabetic neuropathy for years who is actually a LL patient. 

 

Last Lúcio's phenomenon patient I saw, a great the pathologist did a ZN and wrote in the report it was not leprosy in the sections, maybe PAN. I had to call her to tell her that her stain was not working. She ran the positive control and confirmed my suspicion. She had to do ZN again for over 100 cases done with that batch of stain. Imagine trying to convince all labs to do FF instead of ZN.

 

My impression is that only on the reference centers such as Ribeirão Preto School of Medicine and Lauro de Souza Lima things are done properly. 

 

Imagine what is done in England, or in the USA where I would have to teach physicians how to approach a leprosy patient without prejudice. 

 

I was in Harvard for a month, and I was mesmerized by the amount of leprosy patients who would not have a diagnosis if I wasn't there. The pathology session where Dr Meem was showing a "atypical mycobacteriosis" where the dermatology resident did not even test sensibility. Imagine palpating nerves!!! My guess is that if he knew it was a typical BL case he would wear 2 gloves and a N95 mask and where an insulation gown. 

 

Maybe most philosophic publications in Leprosy are done by people who should go to Brazil or India and see leprosy patients everyday for a decade and try to work hard to try to eliminate leprosy. 

 

I am perplexed by the amount of publications done in Netherlands or England with substrate from other countries. You are definitely invited to move to Brazil or India to try to have the real idea of what is really going on. 

 

Leprosy will NEVER be eliminated, my dear friends. 

 

Medical students don't learn how to do a diagnosis or to check a household contact. You cannot learn medicine in theory, reading books or articles. You need to see at least 100 patients with your own hands to have a glimpse of how complex it is. 

 

IMAGINE THE TECHNICIANS, nurses...

 

This mental masturbation about what is cost-effective or what could potentially cause ABX residency is great but should not impact real efforts to eliminate leprosy.

 

Best,

 

Carlos Gustavo Wambier, MD, PhD

Dermatologist

Professor of Dermatology

Department of Medicine

State University of Ponta Grossa



LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com


Tuesday, June 12, 2018

(LML) Manifest against the implementation of MDT-U


Leprosy Mailing List –  June 12,  2018

Ref.:  (LML) Manifest against the implementation of MDT-U  

From:  Claudio Salgado, Marituba, Brazil


Dear Pieter,

The 6 doses shortened MDT treatment for all leprosy patients, called U-MDT, is now being implemented in Brazil despite all the contrary opinions from many different societies, institutions and associations, including the Brazilian Leprosy Society (SBH), that I am the current President, the Brazilian Society of Infectious Diseases (SBI), the Brazilian Academy of Neurology (ABN), the Brazilian Society of Clinical Medicine (SBCM), the Brazilian Medical Association (AMB), the Representatives of the Brazilian Association of Collective Health (ABRASCO), and of the National Counselor of Municipal Health Secretaries (CONASEMS), and the Coordinators of the leprosy National Reference Center at Ribeirão Preto, São Paulo, and of the leprosy National Reference Center at Uberlândia, Minas Gerais.

We all believe there is not enough evidence to implement such a short scheme for all patients. Would you please publish our manifesto against the implementation of U-MDT on the LML?

Thank you.

Claudio Salgado

====================================================
Claudio Guedes SalgadoMDPhD
President of the Brazilian Leprosy Society 2018-2020

Associate Professor 4
Institute of Biological Sciences
Pará Federal University
Dermato-Immunology Laboratory

Av. João Paulo II, 113
Bairro: Dom Aristides
Marituba - Pará - Brasil
Zip Code: 67200-000
Tel: 
55-91-3256-9097

Mobile: 55-91-991465641
E-mails: 
csalgado@ufpa.br and claudioguedessalgado@gmail.com

CV Lattes: http://lattes.cnpq.br/2310734509396125

Lab Map: https://goo.gl/maps/7omyd54wy7z

Facebook: https://www.facebook.com/claudioguedessalgado

====================================================


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact

(LML) Single-dose rifampicin chemoprophylaxis

Leprosy Mailing List – June 12,  2018

Ref.:  (LML) Single-dose rifampicin chemoprophylaxis 

From:  Jaison Barreto, Bauru, Brazil


Dear Pieter,

 

I would like to refer to the letter from Ben Naafs (LML, June 10, 2018) and the letter written by Diana Lockwood and colleagues in PLoS NTDs.

 

About chemoprophylaxis, I would like to know what is its value, once less than 20% of household contacts are effectively evaluated?

 

Also, most of bacilloscopic evaluation, both from histologic sections and slit skin smears, are done under bad conditions. Almost all reference histopathology laboratory's countries I have visited do not know Faraco-Fite for histologic staining of M.leprae, as well as the microbiolgy labs do not know that M.leprae and M.tuberculosis have extremely different acid fast resistance to destaining. 

 

First we need to teach again how to confirm the diagnosis, clinically and by Lab assays. 

 

After that, we can start other steps, as chemoprophylaxis. 

 

Regards,

 

Jaison 


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com


Sunday, June 10, 2018

(LML) Single-dose rifampicin chemoprophylaxis

Leprosy Mailing List – June 10,  2018

Ref.:  (LML) Single-dose rifampicin chemoprophylaxis 

From:  Ben Naafs, Munnekeburen, the Netherlands


 

Dear Pieter

 

 

Some time ago, Dr. Diana Lockwood ask for comments concerning Single-dose rifampicin (SDR) chemoprphylaxis in a letter to LML.

 

Recently, the following article was published: Lockwood DNJ, Krishnamurthy P, Kumar B, Penna G (2018) Single-dose rifampicin chemoprophylaxis protects those who need it least and is not a cost-effective intervention. PLoS Negl Trop Dis 12(6): e0006403. https://doi.org/10.1371/journal.pntd.0006403

 

http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006403

 

 

We strongly recommend reading this publication. It is important that we as leprologists keep reviewing leprosy control policies critically. 

 

 

 

Regards,

 

 

Ben


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com


Saturday, June 9, 2018

(LML) NLEP Newsletter Vol.2 Issue 5

Leprosy Mailing List – June 9,  2018

Ref.:   (LML) NLEP Newsletter Vol.2 Issue 5

From:  Anil Kumar, New Delhi, India


Dear All,

Greetings from Central Leprosy Division (CLD).

 

We are to please to share NLEP Newsletter Vol. 2 Issue 5 which may be seen by clicking on the following link 

http://nlep.nic.in/pdf/Final%20Draft%20NewsLetter%20Jan%20-%20March%202018.pdf

 

I hope that you will find newsletter useful and look forward to your feedback.

 

 

Best regards,

 

Dr. Anil Kumar

DDG(L)


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com


Friday, June 8, 2018

(LML) Leprosy in drama

Leprosy Mailing List – June 8,  2018

Ref.:    (LML) Leprosy in drama

From:  Khalid Al Aboud, Makkah, Saudi Arabia


Dear Pieter,

 

Drama is the overall term referring to everything that is acted, either in theatre, television or films (movies). Its main types are comedy (the laughing face), or tragedy (the weeping face).

The word "cinema", short for cinematography, is often used to refer to filmmaking and the film industry, and to the art of filmmaking itself. The contemporary definition of cinema is the art of simulating experiences to communicate ideas, stories, perceptions, feelings, beauty or atmosphere by the means of recorded or programmed moving images along with other sensory stimulations.

The medical conditions, in general, and skin disorders or changes, in particular, exist in the dramas as a main focus of the play or as distinguishing features of the actors played by them.

(skinema.com) is a website, established in 1996, to explore the skin conditions in movies. 

Dramas have influence the awareness of public about the uncommon or hidden medical disorders. It also showed the social difficulties experienced by those affected by medical conditions.

The life of Joseph Carey Merrick (5 1862 –1890), an English man who is presumed to have been affected by one of the gigantic medical syndromes (like neurofibromatosis or Proteus syndrome), have been depicted in several drama works and films, and now, many people around the world know about his story.

 

This year, In Cannes Film Festival, the film, (Yomeddine), was selected to compete for the Palme d'Or .The film won the François Chalais Prize .

The work is comedy or rather tragicomic film which questions the unfair marginalization of people with leprosy.

 Yomeddine is an Arabic word for (Judgment Day), is unique in several aspects. One of them is that it is played by a real patient (Rady Gamal) affected by leprosy.

The film follows the adventure-filled story of a Coptic leper (Beshay) and his orphaned apprentice. Beshay is left by his father at the gates of a leper colony when he was a little child.

He recovered from leprosy, and come out of Abu Zaabal leper colony in Egypt, goes in search, across Egypt, of the family, who abandoned him.

Yomeddine made a great success in bringing the problems faced by leprosy patients to the surface and to project it in an attractive way to the viewers.

Educational films have been made before on the leprosy but drama films seem to reach to larger sectors of people.

At the end, I may copy may previously published paragraph that ''Only the future will tell what impact this type of drama will continue to have on the public. Doctors and filmmakers should come together to produce what is of benefit as well as of entertainment to public.''

 

Khalid Al Aboud, M.D , Head of Public Health Department, King Faisal hospital, Makkah, Saudi Arabia.E-mail amoa65@hotmail.com

 

References:

1. Ganapati R, Deshpande SS, Revankar CR. Video films for education in leprosy--a preliminary experiment. Indian J Lepr. 1987 Jul-Sep; 59(3):363-4.

2. [Yomeddine].A page on net. Wikipedia.org. Web site.  Available at; https://en.wikipedia.org/wiki/Yomeddine. 2018 June 6. Accessed June 6, 2018.

3. Skinema.Web site. Available at; http://www.skinema.com/evil/. 2018 June 6. Accessed June 6, 2018.

4. Film. A page of the net. Wikipedia.org. Web site .Available at; https://en.wikipedia.org/wiki/Film .2018 June 6. Accessed June 6, 2018.

5. Al Aboud K. Medical dramas – the pros and the cons. Dermatol Pract Concept. 2012 Jan; 2(1): 75–77.Available on line at; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997251/ .

6. Carrell S. 'Elephant Man' brings hundreds of NF cases to light. Am Med News. 1981 Feb 20; 24(7):13-5.


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 


Friday, June 1, 2018

(LML) Online course on NTDs

Leprosy Mailing List – June 1,  2018

Ref.:    (LML) Online course on NTDs

From:  Henk Eggens, Santa Comba Dão, Portugal


 

Dear Pieter,

 

I would like to draw the attention of the LML readers to an online course that will be offered this fall.

 

From the website: 

"The Universitat Oberta de Catalunya (UOC) in collaboration with the World Health Organization (WHO) has developed the programme on Management of Skin Neglected Tropical Diseases.

 

Students will have update information on the epidemiology and surveillance, natural history, diagnostic and treatment strategies of Cutaneous Leishmaniasis (CL), Leprosy (L), Buruli Ulcer (BU) and Yaws (Y).

 

Control disease aspects will also be addressed in line with the WHO regional or global frameworks for the control of the four diseases. Students will analyse and discuss strategies to implement control activities.

 

They will be trained on how to detect the diseases and choose the best available treatment strategies through the resolution of several clinical cases, based on real clinical life in endemic areas, so that they will obtain a strong base for prophylaxis, diagnosis and treatment. The information obtained will be useful for their daily practice.

 

The online course starts in October 2018 and runs until February 2019.

Language: English.

Price €745,00.

Study load: +/- 250 learning hours."

 

For more information, see their website:

 

http://studies.uoc.edu/en/postgraduate-courses/health-sciences/skin-diseases/presentation

 

Kind regards,

 

Henk Eggens, course instructor


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com